COLUMBIA, Md., March 1, 2010 /PRNewswire via COMTEX News Network/ -- Celsion Corporation (Nasdaq: CLSN) today announced that it will initiate a Randomized Phase II Study of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDox(R)) and Radiofrequency Ablation (RFA) for Colorectal Liver Metastases (CRLM). Dr. Steven K. Libutti, Professor and Vice Cha...
COLUMBIA, Md., Feb 22, 2010 /PRNewswire via COMTEX News Network/ -- Celsion Corporation (Nasdaq: CLSN) today announced that a proposal entitled "Application of MRI-guided HIFU to Improve Cancer Chemotherapy with Temperature-Sensitive Targeted Nanomedicines (HIFU-CHEM)" submitted to the Center for Translational Molecular Medicine (CTMM) has been ap...
COLUMBIA, Md., Feb 17, 2010 /PRNewswire via COMTEX News Network/ -- Celsion Corporation (Nasdaq: CLSN), a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox(R), Celsion's heat activated li...
COLUMBIA, Md., Feb 12, 2010 /PRNewswire via COMTEX News Network/ -- Celsion Corporation (Nasdaq: CLSN), a late stage biotechnology drug development company that is leveraging its heat sensitive liposomal technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it would hold a conference c...
COLUMBIA, Md., Feb 10, 2010 /PRNewswire via COMTEX News Network/ -- Celsion Corporation (Nasdaq: CLSN) announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox(R) clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to...
COLUMBIA, Md., Jan 25, 2010 /PRNewswire via COMTEX News Network/ -- CELSION CORPORATION (Nasdaq: CLSN) announced today that it will host a Research and Development Day for the financial community on Wednesday, February 24, 2010 from 7:30 AM - 10:30 AM ET in New York City. The event will be webcast live and archived for 90 days on the Company's web...
COLUMBIA, Md., Jan 21, 2010 /PRNewswire via COMTEX News Network/ -- CELSION CORPORATION (Nasdaq: CLSN) today announced the ThermoDox(R) liver cancer abstract "A Phase I Trial of ThermoDox in Patients Undergoing Radiofrequency Ablation (RFA) of Liver Tumors" has been accepted for oral presentation at the 9th World Congress of the International Hepa...
COLUMBIA, Md., Jan 08, 2010 /PRNewswire via COMTEX News Network/ -- CELSION CORPORATION (Nasdaq: CLSN) today announced the departure of Sean F. Moran, Chief Financial Officer, effective January 8, 2010. Mr. Moran leaves Celsion to pursue other professional opportunities. Timothy J. Tumminello, CPA, the Company's controller, will assume the positi...
COLUMBIA, Md., Dec 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Celsion Corporation (Nasdaq: CLSN) announced today that Celsion, in partnership with the American Liver Foundation (ALF), launched a CME accredited educational webcast for physicians that features recent advances made in the treatment of hepatocellular carcinoma(HCC) and ...
COLUMBIA, Md., Dec 14, 2009 (BUSINESS WIRE) -- Celsion Corporation, a leading oncology drug development company,
announced today that the first patient in China has been enrolled and
treated as part of Celsion's global Phase III ThermoDox HEAT trial for
the treatment of hepatocellular carcinoma (HCC), the most common form of...
COLUMBIA, Md., Dec 03, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development
company, today provided an update on the progress of its pivotal
ThermoDox(R) Phase III "HEAT" trial for the treatment of hepatocellular
carcinoma (HCC), the most common form of primary liver cancer. Followin...
COLUMBIA, Md., Nov 10, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development
company, announced financial results for the third quarter ended
September 30, 2009 and highlighted the progress made in the
commercialization of ThermoDox(R), Celsion's heat activated liposomal
enca...
COLUMBIA, Md., Nov 06, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN), a late stage clinical oncology
development company that is leveraging its heat activated liposomal
technology platform to encapsulate and deliver high concentrations of
proven chemotherapeutics, today announced that it will hold a conference
...
COLUMBIA, Md., Oct 27, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) and Yakult Honsha Co., Ltd. (Tokyo:
2267) announced today that the first patient has been enrolled and
treated in Japan as part of Celsion's global Phase III ThermoDox HEAT
trial for the treatment of hepatocellular carcinoma (HCC), the most
...
COLUMBIA, Md., Oct 20, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that it has completed
a critical regulatory step in the countries of China and Japan to
rapidly enroll patients in its global Phase III ThermoDox trial for the
treatment of Hepatocellular Carcinoma (HCC), also known as primary l...
COLUMBIA, Md., Oct 19, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that it has received
approval from the regulatory agencis in the Philippines and Malaysia for
its Pivotal Phase III primary liver cancer Clinical Trial Application.
Celsion's global Phase III trial is evaluating the efficacy and safety...
COLUMBIA, Md., Oct 15, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that it has received
official approval from China's State Food and Drug Administration
("SFDA") for its Clinical Trial Application for ThermoDox that permits
Celsion to include Chinese clinical trial sites in its Phase III
...
COLUMBIA, Md., Sep 28, 2009 (BUSINESS WIRE) -- Celsion Corporation (the "Company") (NASDAQ: CLSN), an innovative
oncology drug development company dedicated to the development and
commercialization of innovative oncology drugs, today announced that it
has entered into definitive agreements with a select group of
inst...
COLUMBIA, Md., Sept 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- -- Celsion Corporation (Nasdaq: CLSN) announced today initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial evaluating the use of ThermoDox(R) in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast...
ANDOVER, Mass. & COLUMBIA, Md., Sep 23, 2009 (BUSINESS WIRE) -- Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation
(NASDAQ: CLSN) today announced that their joint research program to
evaluate ThermoDox(R) in combination with MR-HIFU (Magnetic Resonance
guided High Intensity Focused Ultrasound) as a combi...
